IPP Bureau

Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma
Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma

By IPP Bureau - July 31, 2022

Shilpa Medicare's Unit III, Advanced Analytical Characterization Laboratory clears US FDA remote record review
Shilpa Medicare's Unit III, Advanced Analytical Characterization Laboratory clears US FDA remote record review

By IPP Bureau - July 31, 2022

The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing

Cipla posts Q1FY23 consolidated PAT at Rs. 686.40 Cr
Cipla posts Q1FY23 consolidated PAT at Rs. 686.40 Cr

By IPP Bureau - July 31, 2022

he company has reported total income of Rs. 5478.62 crores during the period ended June 30, 2022.

Torrent Pharmaceuticals posts Q1FY23 consolidated PAT Rs. 354 Cr
Torrent Pharmaceuticals posts Q1FY23 consolidated PAT Rs. 354 Cr

By IPP Bureau - July 31, 2022

Torrent Pharmaceuticals has reported total income of Rs. 2377 crores during the period ended June 30, 2022.

Cariflex breaks ground on world's largest polyisoprene latex plant in Singapore
Cariflex breaks ground on world's largest polyisoprene latex plant in Singapore

By IPP Bureau - July 29, 2022

Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments

Alniche Lifesciences celebrates 15 anniversary
Alniche Lifesciences celebrates 15 anniversary

By IPP Bureau - July 29, 2022

The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.

GMM Pfaudler Q1FY23 consolidated PAT surges to Rs. 44.51 Cr
GMM Pfaudler Q1FY23 consolidated PAT surges to Rs. 44.51 Cr

By IPP Bureau - July 29, 2022

GMM Pfaudler has reported total income of Rs. 767.73 crores during the period ended June 30, 2022

Biocon Q1FY23 consolidated PAT falls QoQ at Rs. 144.4 Cr
Biocon Q1FY23 consolidated PAT falls QoQ at Rs. 144.4 Cr

By IPP Bureau - July 28, 2022

Biocon has reported total income of Rs. 2217.4 crores during the period ended June 30, 2022.

Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr
Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr

By IPP Bureau - July 28, 2022

Novartis India has reported total income of Rs. 147.44 crores during the period ended June 30, 2022.

Dr. Reddy's launches Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market
Dr. Reddy's launches Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market

By IPP Bureau - July 28, 2022

The Velcade Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022

India has achieved replacement level fertility: Minister Pawar
India has achieved replacement level fertility: Minister Pawar

By IPP Bureau - July 28, 2022

Pawar also unveiled the India Family Planning 2030 vision document and launched the Medical Eligibility Criteria (MEC) Wheel Application, E-Module of Family Planning Logistics Management System (FPLMIS) and Digital Archive on Family Planning under the category of Digital Intervention.

Velocity Clinical Research begins European expansion with German site acquisition
Velocity Clinical Research begins European expansion with German site acquisition

By IPP Bureau - July 28, 2022

Biopharma and CROs to benefit from simplified access to global research sites

Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi
Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi

By IPP Bureau - July 28, 2022

Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate
Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate

By IPP Bureau - July 28, 2022

This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.

Dr Lal Path Labs Q1 FY23 consolidated PAT drops to Rs. 57.7 Cr
Dr Lal Path Labs Q1 FY23 consolidated PAT drops to Rs. 57.7 Cr

By IPP Bureau - July 28, 2022

Dr. Lal Path Labs has reported total income of Rs. 511 crores during the period ended June 30, 2022

Latest Stories

Interviews

Packaging